TY - JOUR
T1 - Engagement of medication users in the development and implementation of digital medication adherence technologies
T2 - a multi-stakeholder study
AU - Hosszú, Dalma
AU - Dima, Alexandra L.
AU - Fernández, Francisca Leiva
AU - Schneider, Marie Paule
AU - van Dijk, Liset
AU - Tóth, Krisztina
AU - Duman, Mark
AU - Davis, Wendy
AU - Andriciuc, Cristian
AU - Egan, Rebecca
AU - Vrijens, Bernard
AU - Kardas, Przemyslaw
AU - Bitterman, Noemi
AU - Mucalo, Iva
AU - Ghiciuc, Cristina Mihaela
AU - Ágh, Tamás
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Background: This study aims to create a comprehensive framework for the development and implementation of digital medication adherence technologies (DMATech), focusing on critical stages where engagement of medication users (MU) is considered meaningful, i.e. adds significant value, as agreed upon by participating stakeholders. Methods: Through a literature review and expert consensus, a framework was outlined covering key DMATech development and implementation phases and steps. An in-person workshop with MU representatives and adherence experts, using the Nominal Group Technique, further refined these stages for MU engagement. Results: The DMATech framework included three phases: ‘Innovation,’ ‘Research and Development,’ and ‘Launch and Implementation,’ each encompassing multiple steps. The workshop, attended by five MU representatives and nine adherence experts, identified critical stages for MU input including context analysis, ideation, proof of concept, prototype creation, DMATech’s iteration, critical evaluation, healthcare implementation, real-world assessment, and improvement. Nevertheless, there was a divergence of consensus regarding the importance of MUs engagement in regulatory, financial, and marketing aspects. Conclusions: This study provides a holistic framework for DMATech development and implementation and underscores the necessity of MU engagement at various stages. Modes of MU engagement cannot be generalized; a case-by-case evaluation of engagement strategies is essential.
AB - Background: This study aims to create a comprehensive framework for the development and implementation of digital medication adherence technologies (DMATech), focusing on critical stages where engagement of medication users (MU) is considered meaningful, i.e. adds significant value, as agreed upon by participating stakeholders. Methods: Through a literature review and expert consensus, a framework was outlined covering key DMATech development and implementation phases and steps. An in-person workshop with MU representatives and adherence experts, using the Nominal Group Technique, further refined these stages for MU engagement. Results: The DMATech framework included three phases: ‘Innovation,’ ‘Research and Development,’ and ‘Launch and Implementation,’ each encompassing multiple steps. The workshop, attended by five MU representatives and nine adherence experts, identified critical stages for MU input including context analysis, ideation, proof of concept, prototype creation, DMATech’s iteration, critical evaluation, healthcare implementation, real-world assessment, and improvement. Nevertheless, there was a divergence of consensus regarding the importance of MUs engagement in regulatory, financial, and marketing aspects. Conclusions: This study provides a holistic framework for DMATech development and implementation and underscores the necessity of MU engagement at various stages. Modes of MU engagement cannot be generalized; a case-by-case evaluation of engagement strategies is essential.
KW - digital health technology
KW - Medication adherence
KW - medication user
KW - multi-stakeholder collaboration
KW - patient engagement
UR - http://www.scopus.com/inward/record.url?scp=85197573434&partnerID=8YFLogxK
U2 - 10.1080/14737167.2024.2373184
DO - 10.1080/14737167.2024.2373184
M3 - Article
C2 - 38934097
AN - SCOPUS:85197573434
SN - 1473-7167
VL - 24
SP - 853
EP - 860
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 7
ER -